November 19, 2026

Why mental health medicines don’t reach patients: lessons from five African countries

CHAI is pleased to release Why mental health medicines don’t reach patients: lessons from five African countries, a new report drawing on a one-year pathfinding program funded by Wellcome and carried out with MedAccess. Through the program, CHAI worked with the governments of Ethiopia, Nigeria, Rwanda, and South Africa, joined by Ghana in mid-2026, to identify why mental health medicines so often fail to reach the people who need them.

Safe, effective mental health medicines have existed for decades, and many are affordable. As one example, a year of treatment with haloperidol, a widely used antipsychotic, costs between US$3 and US$14 per patient. Yet in low-income countries, fewer than one in ten people living with psychosis receive care.

The program found the obstacles lie in how medicines are priced, bought, supplied, and prescribed, and that these problems reinforce one another. The report shares what CHAI found, what governments have already done in response, and where further action is needed. One example of early progress comes from Ethiopia, where the government set up a monthly stock-monitoring group. Across 11 facilities, a 33-item list of mental health medicines was available on average 54 percent of the time in May 2026, rising to 76 percent in September 2026.

Read the report

Back To Top